CVS Health Corporation's stock is rated a soft Buy due to improved profitability and valuation. The company reported a 6.7% increase in revenue to $206.5 billion and more than doubled its net income, driven by operational improvements in its segments. The Health Care Benefits segment reversed previous losses, helped by strategic exits and a lower medical benefit ratio of 86%. Management projects 2026 revenue of at least $414 billion and adjusted EPS between $7.90 and $8.10, expecting strong cash flow despite ongoing high medical costs.
CVS Health's market capitalization stands at $109.81 billion as of September 26, 2026, 05:11 WIB, with a dividend yield of 3.1%. The stock price on Pluang is USD 89.15, showing a strong 1-day gain of 4.82%, supported by high trading volume of 7,225,910 shares. Pluang investors hold CVS shares for an average of 83 days, with current order activity fully skewed to buying as of the same timestamp.
